The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN, discusses the efforts of the myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) International Working Group (IWG) to address the unmet medical needs of patients with MDS/MPN overlap syndromes by revising response criteria and developing new clinical study protocols. Dr Savona mentions the ABLN-MARRO master clinical trial (NCT04061421), with sub-studies investigating various combination therapies in these hematological malignancies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The MDS/MPN-IWG is focused on bringing new medicines to patients who have overlap syndromes. MDS/MPNs, such as CMML, are vastly untreated. They’re real unmet medical needs. So really the first step in trying to bring new medicines to bear is to understand how they work. And we wrote the response criteria in 2015 which were helpful, but now it’s time to revise these criteria from the learnings we’ve had and we’re rewriting these new criteria that we publish in 2026 to be able to be more efficient in the drug development process...
The MDS/MPN-IWG is focused on bringing new medicines to patients who have overlap syndromes. MDS/MPNs, such as CMML, are vastly untreated. They’re real unmet medical needs. So really the first step in trying to bring new medicines to bear is to understand how they work. And we wrote the response criteria in 2015 which were helpful, but now it’s time to revise these criteria from the learnings we’ve had and we’re rewriting these new criteria that we publish in 2026 to be able to be more efficient in the drug development process. ABNLMARRO is a clinical study protocol written by the MDS/MPN-IWG. This is an international study. ABNLMARRO is a clinical study protocol written by the MDS/MPN-IWG. This is an international study. ABNLMARRO 001 is a basket study testing ASTX727, or cedazuridine plus decitabine, an oral hypomethylating agent, together with a variety of different novel compounds. ABNLMARRO 002, which was announced here at ASH, is a randomization of pacritinib and hydroxyurea in patients with CMML. And ABNLMARRO 003 will be starting soon. These studies will be operated around the world, given that this is an uncommon disease, and there are experts in the UK, EU, Canada, Australia, and elsewhere.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
